PGI2 USE OF DIFFERENT STATISTICAL APPROACHES TO COMPARE REAL-WORLD OUTCOMES ASSOCIATED WITH VEDOLIZUMAB VERSUS INFLIXIMAB IN BIOLOGIC-NAIVE PATIENTS WITH INFLAMMATORY BOWEL DISEASE
Abstract
Authors
D. Latremouille-Viau R. Burne S. Shi H. Patel